The next era of obesity care is not about choosing between GLP-1s, surgery or lifestyle interventions
GLP-1 agonists also improve cardiovascular outcomes in patients with type 2 diabetes or obesity, a benefit not consistently demonstrated for berberine
They can only look at safety. It is not typical for an HHS Secretary to interfere with an FDA committee roster
Systematic assessment of environmental risk factors for bipolar disorder: an umbrella review of systematic reviews and meta-analyses
Appetite reduction begins early, but the biggest changes often start after the first month In this post, I'll explain what the GLP-1 average weight loss per month looks like, how results evolve over time, and how to safely support your progress from home
Maganto-Garca, E., Tarrio, M